ERAS Stock Risk & Deep Value Analysis
Erasca Inc
DVR Score
out of 10
What You Need to Know About ERAS Stock
We analyzed Erasca Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ERAS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ERAS Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is further negative clinical trial outcomes, particularly with ERAS-0015. A patient death has already occurred, and if more severe adverse events or efficacy issues arise, it could lead to trial halts, abandonment of key programs, or significant delays, ultimately jeopardizing the company's entire valuation.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Patient death in a clinical trial, causing a ~55% stock decline.
- ⚠
Preliminary ERAS-0015 data perceived as 'unfavorable' for pancreatic cancer, despite positive NSCLC results.
- ⚠
Allegation from Revolution Medicines concerning improper preclinical data comparisons, suggesting competitive friction.
- ⚠
Continued insider selling by the Erasca Foundation and an executive after a significant stock run-up.
Upcoming Risk Events
- 📅
Further negative clinical trial data or adverse events for ERAS-0015 or other programs
- 📅
Worsening of the competitive dispute with Revolution Medicines, potentially leading to litigation
- 📅
Failure to secure additional funding without significant dilution if cash burn accelerates
When to Reconsider
- 🚪
Further severe adverse events or trial halts in ongoing clinical studies.
- 🚪
Significant dilution from a capital raise without corresponding positive clinical milestones.
- 🚪
Consistently deteriorating Free Cash Flow (FCF) burn rate without a clear path to drug approval or major partnership.
- 🚪
Sustained breach of the $8.00 support level, indicating further market loss of confidence.
Unlock ERAS Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Erasca presents a high-risk, high-reward opportunity in the oncology space, specifically targeting the historically challenging RAS/MAPK pathway with novel therapies. Despite significant recent clinical setbacks and competitive allegations, the company maintains a strong cash position and a vision for future market leadership. A successful recovery in clinical trials for ERAS-0015, particularly with positive mid-May data, could re-ignite its growth trajectory and justify its focus on this critical unmet medical need.
Is ERAS Stock Undervalued?
Unlock the full AI analysis for ERAS
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ERAS Price Targets & Strategy
12-Month Target
$14.50
Bull Case
$25.00
Bear Case
$6.00
Valuation Basis
Based on a ~0.8x multiple of the median analyst price target ($17.88), reflecting cautious recovery and re-rating potential.
Entry Strategy
Consider accumulation in the $9.50-$10.50 range, especially on any dips following immediate post-news volatility or if mid-May ERAS-0015 data provides clarity.
Exit Strategy
Take 50% profit at $18-$22 if clinical progress resumes; implement a stop-loss if the price drops below $8.00.
Portfolio Allocation
3-5% for aggressive growth-oriented portfolios, given the very high-risk, high-reward profile.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does ERAS Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Eroding
Moat Sources
2 Identified
The moat is primarily built on intellectual property around novel compounds. Its durability is being challenged by fierce competition (e.g., Revolution Medicines) and recent clinical setbacks (patient death, mixed data perception) which could weaken its 'best-in-class' claim and extend development timelines.
Moat Erosion Risks
- •Faster or more effective drug development by competitors (e.g., RMC-6236).
- •Failure of clinical trials to demonstrate significant differentiation or superior safety/efficacy.
- •Patent challenges or loss of intellectual property protection.
ERAS Competitive Moat Analysis
Sign up to see competitive advantages
ERAS Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral, likely mixed with increased caution after recent negative news, but prior bullishness may persist among long-term holders.
Institutional Sentiment
Mixed to Positive. Recent analyst ratings include 7 Buys, 1 Hold, 2 Sells. Stifel Nicolaus and JPMorgan had recent upgrades/reaffirmations, while Morgan Stanley has a more conservative $10 target.
Insider Activity (Form 4)
Erasca Foundation sold 8,333 common shares ($116,855) on 2026-03-16, and other sales on 2026-02-17 and 2026-01-15. Insider Shannon Morris sold 20,000 shares ($300,800) on 2026-03-04.
Options Flow
Normal options activity; no specific unusual volume or skew indicating significant institutional positioning was highlighted in the provided data.
Earnings Intelligence
Next Earnings
2026-05-12
Surprise Probability
Medium
Historical Earnings Pattern
No specific historical pattern mentioned in the research. Given its early stage, earnings reactions are likely highly volatile, driven by clinical updates and cash position rather than traditional revenue/EPS beats/misses.
Key Metrics to Watch
Competitive Position
Top Competitor
Revolution Medicines (RMC)
Market Share Trend
Not yet established; company is pre-revenue and striving to capture future market share in the RAS/MAPK pathway with its lead assets.
Valuation vs Peers
Difficult to compare directly without forward P/E, EV/EBITDA, or P/S for both, but Erasca's -23.83 trailing P/E highlights its pre-profitability. Its current valuation is heavily tied to pipeline potential, which has recently faced setbacks, potentially making it appear less attractive than peers with clearer clinical paths.
Competitive Advantages
- •Targeting a historically challenging and high-value RAS/MAPK pathway in oncology.
- •Differentiated molecular glue approach (ERAS-0015) aiming for pan-RAS activity.
- •Experienced leadership team with deep oncology expertise.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ERAS Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (2026-05-12)
- •Updated ERAS-0015 Phase 1 monotherapy data presentation (Mid-May 2026)
- •Resolution or clarification regarding Revolution Medicines' allegation
Medium-Term (6-18 months)
- •Advancement of ERAS-0015 into later-stage trials or expansion into new indications
- •Potential strategic partnerships or licensing deals for pipeline assets
- •Progress on other pipeline candidates (e.g., ERAS-801, ERAS-4001)
Long-Term (18+ months)
- •First drug approval and commercialization, establishing a revenue base
- •Dominant market share in specific RAS/MAPK mutant cancer indications
- •Development of a broad, multi-asset oncology pipeline leveraging proprietary insights
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ERAS?
- ✓
Consistent positive clinical updates for ERAS-0015 and other pipeline assets (e.g., clear efficacy, manageable safety profile)
- ✓
New strategic partnerships or licensing deals that validate pipeline value and provide non-dilutive funding.
- ✓
Any insider buying activity, signaling renewed confidence from management.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Erasca Inc Makes Money
Erasca is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for cancer, particularly by targeting the RAS/MAPK pathway. The company generates no revenue currently but aims to make money through the successful development and regulatory approval of its drug candidates, followed by direct sales or through licensing agreements with larger pharmaceutical companies. Its business model relies heavily on significant R&D investment, successful clinical trials, and eventually, market adoption of its proprietary cancer treatments.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Erasca Inc (ERAS)?
As of May 4, 2026, Erasca Inc has a DVR Score of 5.9 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Erasca Inc?
Erasca Inc's market capitalization is approximately $3.1B..
What is the risk level for ERAS stock?
Our analysis rates Erasca Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the ERAS DVR analysis updated?
Our AI-powered analysis of Erasca Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 4, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ERAS (Erasca Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.